A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary)
- Indications Carcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Mar 2017 Status changed from suspended to active, no longer recruiting.
- 11 Aug 2016 Status changed from recruiting to suspended for assessment.